Your browser doesn't support javascript.
[The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Wen, C Y; Xie, Z W; Li, Y P; Deng, X L; Chen, X T; Cao, Y; Ou, X; Lin, W Y; Li, F; Cai, W P; Li, L H.
  • Wen CY; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Xie ZW; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Li YP; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Deng XL; Intensive Care Unit, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Chen XT; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Cao Y; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Ou X; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Lin WY; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Li F; Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Cai WP; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
  • Li LH; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou 510060,China.
Zhonghua Nei Ke Za Zhi ; 59(8): 605-609, 2020 Aug 01.
Article in Chinese | MEDLINE | ID: covidwho-1556260
Semantic information from SemMedBD (by NLM)
1. arbidol TREATS COVID-19
Subject
arbidol
Predicate
TREATS
Object
COVID-19
2. lopinavir / Ritonavir TREATS COVID-19
Subject
lopinavir / Ritonavir
Predicate
TREATS
Object
COVID-19
3. COVID-19 PROCESS_OF World
Subject
COVID-19
Predicate
PROCESS_OF
Object
World
4. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
5. Throat swab sample LOCATION_OF Nucleic Acids
Subject
Throat swab sample
Predicate
LOCATION_OF
Object
Nucleic Acids
6. Nucleic Acids PART_OF 2019 novel coronavirus
Subject
Nucleic Acids
Predicate
PART_OF
Object
2019 novel coronavirus
7. Nucleic Acids ASSOCIATED_WITH Symptoms
Subject
Nucleic Acids
Predicate
ASSOCIATED_WITH
Object
Symptoms
8. arbidol NEG_TREATS Symptoms
Subject
arbidol
Predicate
NEG_TREATS
Object
Symptoms
9. lopinavir / Ritonavir NEG_TREATS Symptoms
Subject
lopinavir / Ritonavir
Predicate
NEG_TREATS
Object
Symptoms
10. arbidol TREATS COVID-19
Subject
arbidol
Predicate
TREATS
Object
COVID-19
11. lopinavir / Ritonavir TREATS COVID-19
Subject
lopinavir / Ritonavir
Predicate
TREATS
Object
COVID-19
12. COVID-19 PROCESS_OF World
Subject
COVID-19
Predicate
PROCESS_OF
Object
World
13. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
14. Throat swab sample LOCATION_OF Nucleic Acids
Subject
Throat swab sample
Predicate
LOCATION_OF
Object
Nucleic Acids
15. Nucleic Acids PART_OF 2019 novel coronavirus
Subject
Nucleic Acids
Predicate
PART_OF
Object
2019 novel coronavirus
16. Nucleic Acids ASSOCIATED_WITH Symptoms
Subject
Nucleic Acids
Predicate
ASSOCIATED_WITH
Object
Symptoms
17. arbidol NEG_TREATS Symptoms
Subject
arbidol
Predicate
NEG_TREATS
Object
Symptoms
18. lopinavir / Ritonavir NEG_TREATS Symptoms
Subject
lopinavir / Ritonavir
Predicate
NEG_TREATS
Object
Symptoms
ABSTRACT

Objective:

To evaluate the efficacy and safety of lopinavir/ritonavir (LPV/r) and arbidol in treating patients with coronavirus disease 2019 (COVID-19) in the real world.

Methods:

The clinical data of 178 patients diagnosed with COVID-19 admitted to Guangzhou Eighth People's Hospital from January 20 to February 10, 2020 were retrospectively analyzed. According to patient's antiviral treatment regimens, 178 patients were divided into 4 groups including LPV/r group (59 patients), arbidol group (36 patients), LPV/r plus arbidol combination group (25 patients) and the supportive care group without any antiviral treatment (58 patients). The primary end point was the negative conversion time of nucleic acid of 2019 novel coronavirus (2019-nCoV) by pharyngeal swab.

Results:

The baseline parameters of 4 groups before treatment was comparable. The negative conversion time of viral nucleic acid was (10.20±3.49), (10.11±4.68), (10.86±4.74), (8.44±3.51) days in LPV/r group, arbidol group, combination group, and supportive care group respectively (F=2.556, P=0.058). There was also no significant difference in negative conversion rate of 2019-nCoV nucleic acid, the improvement of clinical symptoms, and the improvement of pulmonary infections by CT scan (P>0.05). However, a statistically significant difference was found in the changing rates from mild/moderate to severe/critical type at day 7 (χ(2)=9.311, P=0.017), which were 24%(6/25) in combination group, 16.7%(6/36) in arbidol group, 5.4%(3/56) in LPV/r group and 5.2%(3/58) in supportive care group. Moreover, the incidence of adverse reactions in three antiviral groups was significantly higher than that in supportive care group (χ(2)=14.875, P=0.002).

Conclusions:

Antiviral treatment including LPV/r or arbidol or combination does not shorten the negative conversion time of 2019-nCoV nucleic acid nor improve clinical symptoms. Moreover, these antiviral drugs cause more adverse reactions which should be paid careful attention during the treatment.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Observational study / Randomized controlled trials / Risk factors Limits: Humans Language: Chinese Journal: Zhonghua Nei Ke Za Zhi Year: 2020 Document Type: Article Affiliation country: Cma.j.cn112138-20200227-00147

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Observational study / Randomized controlled trials / Risk factors Limits: Humans Language: Chinese Journal: Zhonghua Nei Ke Za Zhi Year: 2020 Document Type: Article Affiliation country: Cma.j.cn112138-20200227-00147